Hosted on MSN26d
45 Degrees North: The Rural Cancer CommuteLynn has multiple myeloma, a blood cancer in which ... reported to the hospital for two outpatient procedures. First, a PICC line was inserted in her arm. That would provide intravenous access ...
Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood cells that produce infection-fighting antibodies. Multiple myeloma is not hereditary, meaning it is not passed ...
Pomalyst (pomalidomide) is a prescription drug that’s used to treat multiple myeloma in adults. Pomalyst is also available as a generic drug. Pomalyst comes as an oral capsule. The active ...
Linvoseltamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody. The BLA resubmission was needed as the original application could not be approved due to manufacturing ...
2h
Zacks.com on MSNRegeneron Gets Positive CHMP Opinion for Multiple Myeloma DrugRegeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...
Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma ...
Saad Usmani, Chief of MSK's Myeloma Service, says there are far more treatment options for multiple myeloma today compared with just 20 years ago. Note: This story was originally published in 2022 and ...
and dexamethasone for first-line multiple myeloma therapy. Although both trials represented significant advances in the treatment of multiple myeloma, they highlighted an ongoing problem with ...
Here’s my take on myeloma-related studies that I’m excited about now and in the year ahead, with a focus on smoldering multiple myeloma (SMM), newly diagnosed disease, and first relapse.
The result comes shortly after Sarclisa was shown to add a benefit when added to another first-line multiple myeloma regimen for transplant-ineligible patients – VRd (Takeda’s Velcade ...
This treatment is indicated for patients with relapsed and/or refractory multiple myeloma (R/R MM) who have received three or more prior lines of therapies. Equecabtagene Autoleucel (trade name ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results